aTyr Pharma, a rare disease biotherapeutics enterprise, has announced the appointment of David Weiner as chief medical officer.
Dr Weiner (pictured) has previously held key leadership positions at Proteostasis, Merck Serono and Acadia Pharmaceuticals. His background includes rare disease and extensive clinical trial experience. Dr Weiner will spearhead aTyr's efforts to advance its Physiocrine biology into meaningful therapeutics to treat rare, grave immune disorders.
“At a key time for advancing our pipeline of therapeutics in the rare diseases arena, Dr Weiner brings to our team a strong drug development background and important clinical experience, and he will lead, implement and execute aTyr's clinical development programs,” said John Mendlein, chief executive and executive chairman of aTyr Pharma. “We welcome Dr Weiner to the team. He is driven to make life changing therapies for patients and will play an important role in our quest for meaningful medicines for patients with little or no treatment options at this time.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze